ORYZON GENOMICS, S.A. from 16/07/2019 to 16/07/2019 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 16/07/2019 09:05 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks ORYZON announces that data from its ETHERAL Phase IIa clinical trial of vafidemstat in Alzheimer’s patients were presented yesterday at the Alzheimer´s Association International Conference (AAIC-2019) Register number: 280225